China Medical Technologies (中国医疗技术公司) reported that its SPR-based Analysis System passed a milestone in its quest for SFDA approval. The system received a Quality Testing Certificate, indicating it met or surpassed all the safety and performance parameters required by the SFDA. The system has other tests ahead of it. China Medical continues to expect that approval for the SPR system and the HPV chip will be awarded before the end of 2009. China Medical paid $345 million to purchase the system in October 2008. More details...

Stock Symbol: (NSDQ: CMED)